data patients leukemia participating phase study hum195 labeled emitter 213bi NUMBER min used estimate pharmacokinetics dosimetry trial using emitter humans linear energy transfer alpha particles hundredfold greater beta emissions range tissue approximately microm methods activity administered patients ranged NUMBER NUMBER gbq patient imaging initiated start injection thirty images followed images collected dynamic mode NUMBER photopeak window centered NUMBER kev used blood samples collected NUMBER h postinjection counted gamma counter contours liver spleen drawn anterior posterior views portion spine posterior views organs visualized results percentage injected dose liver spleen volumes increased rapidly min constant value remaining hour imaging yielding rapid uptake followed plateau antibody uptake curves kinetic curves integrated yield cumulated activity mean energy emitted nuclear transition 213bi daughters adjusted relative biologic effectiveness NUMBER alpha emissions multiplied cumulated activity yield absorbed dose equivalent photon dose total body determined calculating fraction absorbed dose equivalent liver spleen volumes ranged NUMBER NUMBER NUMBER NUMBER sv respectively marrow leukemia mean dose ranged NUMBER NUMBER sv dose photons ranged NUMBER x NUMBER x gy conclusion study shows patient imaging 213bi emitter labeled hum195 possible used derive pharmacokinetics dosimetry absorbed dose ratio marrow liver spleen volumes body greater commonly observed radionuclides used radioimmunotherapy activity escalation alpha particle half life alpha particle NUMBER NUMBER NUMBER min NUMBER min NUMBER NUMBER photon absorbed total body NUMBER NUMBER NUMBER NUMBER alpha particle 213bi hum195 NUMBER fold beta emitting